Caribou Biosciences IPO
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company developing programmed allogeneic cell therapies. The company focuses on off-the-shelf CAR-T and CAR-NK cell therapies for treating hematologic malignancies and solid tumors. Investors are interested in its differentiated CRISPR platform and potential to address limitations of current cell therapies.
Key Facts
| Industry | Biotechnology |
| Founded | 2011 |
| Headquarters | Berkeley, CA |
| Employees | ~200 |
| Website | cariboubio.com |
| Funding | Public company (NASDAQ: CRBU). IPO raised $248M in 2021 |
About Caribou Biosciences
Caribou Biosciences is a clinical-stage CRISPR genome-editing company developing engineered cell therapies for cancer treatment, with a focus on allogeneic CAR-T cell therapies derived from healthy donors rather than patients. The company's chRDNA platform combines CRISPR gene editing with proprietary technologies to create off-the-shelf cell therapies that can be manufactured at scale and administered without the lengthy patient-specific production times required by autologous treatments.
Founded by CRISPR co-inventor Jennifer Doudna, Caribou has advanced multiple programs into clinical trials, including CB-010 for B-cell malignancies and CB-011 for multiple myeloma. The company's approach addresses key limitations of current CAR-T therapies, including manufacturing complexity, cost, and treatment delays. Caribou went public in 2021 and continues to advance its pipeline while exploring applications of its genome-editing platform beyond oncology, including potential treatments for autoimmune diseases.
IPO Status
Caribou Biosciences completed its initial public offering in July 2021, trading on NASDAQ under the ticker symbol CRBU. The company raised approximately $200 million in its IPO, pricing shares at $16 each, which was at the high end of its expected range of $14-16. Since going public, the stock has experienced significant volatility typical of biotech companies, with performance tied to clinical trial updates and regulatory milestones. The company continues to advance its pipeline of allogeneic cell therapies through various stages of clinical development.
Competitors
Frequently Asked Questions
Does Caribou Biosciences have a stock?
Yes, Caribou Biosciences completed its IPO in July 2021. The company has been publicly traded on NASDAQ under the ticker CRBU since then.
When is the Caribou Biosciences IPO date?
Caribou Biosciences already completed its IPO on July 23, 2021. The company is currently trading as a public company on NASDAQ.
How can I buy Caribou Biosciences stock?
You can buy Caribou Biosciences stock through any brokerage account since it trades publicly on NASDAQ under the ticker CRBU. The stock is available during regular market hours and can be purchased like any other publicly traded security.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts